

Match Overview

1	Internet 54 words crawled on 07-Feb-2017 eprints.soton.ac.uk	1%
2	Crossref 53 words Shaun E. Gruenbaum , Eric C. Chen , Mani Ratnesh Singh Sandhu , Ketaki Deshpande , Roni Dhaher , Denise Hersey ...	1%
3	Internet 49 words crawled on 26-Mar-2020 www.ncbi.nlm.nih.gov	1%
4	Internet 43 words crawled on 17-Jun-2019 medicine.exeter.ac.uk	1%
5	Internet 37 words crawled on 29-May-2020 www.karger.com	1%
6	Internet 27 words crawled on 10-Dec-2019 onlinelibrary.wiley.com	1%
7	Internet 25 words crawled on 15-Mar-2019 jnbs-journal.com	1%
8	Crossref 21 words Ruriko Igata-Yi , Tomohide Igata , Kouko Ishizuka , Takemi ... imura et al. "Apolipoprotein E genotype and psychosis", B	<1%
9	Crossref 20 words &NA;: "New Research Poster Session :", American Journal of Geriatric Psychiatry , 03/2011	<1%
10	Internet 15 words crawled on 21-Dec-2019 scholarscompass.vcu.edu	<1%
11	Internet 14 words crawled on 23-Nov-2019 chestervetclinic.com	<1%
12	Internet 14 words	1%

Name of Journal: *World Journal of Psychiatry*

Manuscript NO: 54597

Manuscript Type: SYSTEMATIC REVIEWS

Pimavanserin for the treatment of psychosis in Alzheimer's disease: A literature review

Srinivasan S *et al.* Pimavanserin for the treatment of psychosis in AD

Shilpa Srinivasan, Rajesh R Tampi, Kripa Balaram, Arushi Kapoor

Abstract

BACKGROUND

Alzheimer's disease (AD) is among the most prevalent forms of dementia in the world and neuropathological studies suggest similar high prevalence of mixed (AD + vascular) dementias. Approximately 25%-50% of individuals with AD develop psychosis sometime during their illness. The presence of psychosis in AD worsens outcomes. Currently there are no United States Food and Drug

Pimavanserin for the treatment of psychosis in Alzheimer



ALL

IMAGES

VIDEOS

939,000 Results

Any time ▾

Evidence for using pimavanserin for the treatment of ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6560499>

Jun 10, 2019 · Core tip: **Pimavanserin** is an atypical **antipsychotic** that was the first medication to be approved by the Food and Drug Administration for the **treatment** of hallucinations and delusions associated with **Parkinson's disease psychosis (PDP)**. There are only two published trials that have evaluated the use of **pimavanserin** among individuals with **PDP**.

Author: Rajesh R Tampi, Deena J Tampi, Jua...

Publish Year: 2019

Pimavanserin for Parkinson's Disease psychosis: Effects ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6261678>

Nov 02, 2018 · A recent study for PIM in patients with **Alzheimer's disease psychosis** showed benefit,⁴² and another study of PIM for **psychosis** in multiple dementing disorders is ongoing (NCT03325556). In addition to the post-hoc nature of this analysis, additional caveats need consideration.

Cited by: 2

Author: Alberto J. Espay, Michael T. Guskey, Jam...

Publish Year: 2018

Pimavanserin for the treatment of psychosis in Alzheimer's disea



ALL

IMAGES

VIDEOS

1,310,000 Results

Any time ▾

Pimavanserin: Potential Treatment For Dementia-Related ...

<https://www.ncbi.nlm.nih.gov/pubmed/30298184>

Currently, no **pharmacologic treatment** is approved for **dementia-related psychosis**. Atypical **antipsychotics** are frequently used to **treat** these **disorders**, despite significant safety concerns. **Pimavanserin**, a selective 5-HT_{2A} inverse agonist/antagonist, was approved in the U.S. for **treating hallucinations** and delusions associated with **Parkinson's disease psychosis (PDP)**.

Cited by: 2**Author:** Jeffrey L Cummings, C. Ballard, P. Tario...**Publish Year:** 2018

Pimavanserin, a novel antipsychotic for management of ...

<https://www.ncbi.nlm.nih.gov/pubmed/28817967>

Pimavanserin is the first **FDA** approved **drug** for the **treatment** of **hallucinations and delusions** associated with **PDP**. Areas covered: For this review, a MEDLINE literature search (via **PubMed**) and information provided by **ACADIA Pharmaceuticals** were used. This review will discuss the **pathophysiology** and current management of **PDP**.

Cited by: 5**Author:** Yasaman Kianirad, Tatyana Simuni**Publish Year:** 2017

Pimavanserin in Parkinson's Disease-induced Psychosis: A ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6760879>

Jul 28, 2019 · After reviewing existing literature, pimavanserin at a total daily dose of **34 mg** (split into 17 mg two times a day) is useful for treating psychosis (**hallucinations and delusions**) in PD patients. **Dose changes** may be required when pimavanserin is used with **CYP450 inhibitor** or **inducer**.

Author: Rikinkumar S Patel, Jatminderpal Bh...**Publish Year:** 2019

PEOPLE ALSO ASK

Pimavanserin for the treatment of psychosis in Alzheim



ALL

IMAGES

VIDEOS

MAPS

NEWS

SHOPPING

1,310,000 Results

Any time ▾

Pimavanserin: Potential Treatment For Dementia-Related ...

<https://www.ncbi.nlm.nih.gov/pubmed/30298184>

Currently, no **pharmacologic treatment** is approved for **dementia-related psychosis**. Atypical **antipsychotics** are frequently used to **treat** these **disorders**, despite significant safety concerns. **Pimavanserin**, a selective 5-HT_{2A} inverse agonist/antagonist, was approved in the U.S. for **treating hallucinations** and delusions associated with **Parkinson's disease psychosis (PDP)**.

Cited by: 2

Author: Jeffrey L Cummings, C. Ballard, P. Tariot, ...

Publish Year: 2018

Pimavanserin, a novel antipsychotic for management of ...

<https://www.ncbi.nlm.nih.gov/pubmed/28817967>

Pimavanserin is the first **FDA** approved **drug** for the **treatment** of **hallucinations and delusions** associated with **PDP**. Areas covered: For this review, a MEDLINE literature search (via **PubMed**) and information provided by **ACADIA Pharmaceuticals** were used. This review will discuss the **pathophysiology** and current management of **PDP**.

Cited by: 5

Author: Yasaman Kianirad, Tatyana Simuni

Publish Year: 2017

Pimavanserin, a novel antipsychotic for management of ...

<https://www.tandfonline.com/doi/abs/10.1080/17512433.2017.1369405>

Oct 31, 2017 - **Pimavanserin** is the first **FDA** approved **drug** for the **treatment** of **hallucinations and delusions** associated with **PDP**. Areas covered : For this review, a MEDLINE literature search (via **PubMed**) and information provided by **ACADIA Pharmaceuticals** were used. This review will discuss the **pathophysiology** and current management of **PDP**.

Cited by: 5

Author: Yasaman Kianirad, Tatyana Simuni

Publish Year: 2017

PEOPLE ALSO ASK

Does pimavanserin work for your Alzheimer s?



Pimavanserin

Pimavanserin is used to treat the symptoms of a certain mental/mood disorder that might occur with Parkinson's disease.

Precautions



Side Effects



Interactions



Warnings

Brand names: Nuplazid

Pregnancy category: Pregnancy Category D (FDA) (Positive evidence of risk)

People also search for

clozapine

cariprazine

aripiprazole

Roluperidone

risperidone

See more ▾

Data from First Databank and others [Learn more](#)

Consult a medical professional for advice

[Suggest an edit](#)